Navigation Links
DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
Date:5/4/2013

Los Angeles, CA (PRWEB) May 04, 2013

The diabetes drug safety advocates at DrugRisk.com are announcing updated information for patients who have taken the medication Byetta. A recent study suggests the drug may have higher occurrence rates of pancreatic cancer and thyroid cancer than traditional treatments.

DrugRisk was created to improve the safety of those taking popular prescription drugs by providing the latest warnings, recalls, studies and legal news. Patients can see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a twice-daily injectable medication released in 2005 to help those with type-2 diabetes control blood sugar. It generated sales of over $300 million last year, when it was purchased with Amylin Pharmaceuticals by Bristol-Myers Squibb*.

However, DrugRisk has added a 2011 study from UCLA indicating Byetta could increase the risk of pancreatic cancer by 290% and thyroid cancer by 473%**. The Journal for the American Medical Association also recently published findings showing these drugs can double the risk of pancreatitis, a major risk factor for pancreatic cancer***.

Now, DrugRisk has added a new report by the Institute for Safe Medication Practices, which found in an analysis of FDA reports that patients were over 20 times as likely to report pancreatitis, pancreatic cancer or thyroid cancer from Januvia than from traditional diabetes treatment like metformin****.

Due to the number of patients filing a Byetta lawsuit alleging cancer, lawyers have asked that cases be consolidated to a special federal multi-district court in California****. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Byetta is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
**Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
***JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
****Institute for Safe Medication Practices, 4/18/13; ismp.org/QuarterWatch/pdfs/2012Q3.pdf
*****JPML, 4/5/13; cdn.aboutlawsuits.com/wp-content/uploads/2013-04-05-Incretin-Mimetics-MDL.pdf

Read the full story at http://www.prweb.com/releases/byetta-lawsuit/side-effects/prweb10699747.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
2. DrugRisks News Update: Bayer Loses Yaz Patent as Blood Clot Settlements Continue
3. DrugRisk Update: Court Asks for Pradaxa Lawsuit Test Cases
4. DrugRisks Adds Update From Court Ordering Mediation of Stryker Hip Lawsuits
5. DrugRisk Announces Launch of Byetta Cancer Resource Center
6. DrugRisks Update: Federal Court Schedules First Mirena Lawsuit Hearing
7. DrugRisk Announces Addition of Januvia Cancer Resource Center
8. DrugRisks Legal Update: Jury to Decide Actos Cancer Trial This Week
9. DrugRisks Update: Doctor Testifies Actos Main Cause of Bladder Cancer in Trial
10. DrugRisk Announces Launch of DePuy Hip Resource Center
11. DrugRisk Update: Mirena Maker Asks to Keep Lawsuits With Local Court, Judge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
(Date:3/29/2017)... ... ... Hamlin Dental Group, multi-location dental office in North Hollywood , Van ... safe and effective options, and can be used alone or in conjunction with other ... care. , Dr. Hamid Reza of Hamlin Dental Group offers other treatments as well, ...
(Date:3/29/2017)... ... March 29, 2017 , ... VisualSP has helped over 1.5 million ... only option for on-premises installation of its Help System for SharePoint was at the ... system into the entire tenant. , The company recently released a modified version ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
(Date:3/28/2017)... ... March 28, 2017 , ... City trips have ... World Travel Trends Report). As travelers visit both urban destinations, they are faced ... prolonged sun exposure. In response, the outdoor industry has blurred the lines between ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy ... announced that it has named Leah Bailey ... all divisions of the company. With more ... the previous 8 years focused on health care, Bailey ... her tenure at Prime, Bailey advised the PBM, Specialty, ...
(Date:3/29/2017)... Varian Medical Systems (NYSE: VAR ) ... quarter of fiscal year 2017 following the close of regular ... be followed by a teleconference available to all interested parties ... to the conference call webcast will be available on the ... call and replay: ...
Breaking Medicine Technology: